Our magazine is free!

for living with diabetes

Sanofi invests in Enable Injections

Sanofi has lead a round of investment for Enable Injections’ enFuse, an on-body drug-delivery system. Previous investors, including the Cleveland Clinic and CincyTech, and private investors also participated in the round. Enable Injections developed a drug-delivery device that’s designed to deliver doses of biologics.*

Enable Injections set out to create a product that allows a pharmaceutical company to give patients the most positive administration experience possible. The company leverages its device as a way for biopharma companies to differentiate their drugs and improve compliance among users.

John Rice, Enable Injections board member & CincyTech’s director of life sciences, says: “Enable Injections has made significant progress and is now a clinical-stage company with its initial products in human clinical trials. This financing will enable the company to advance to a commercial scale and bring its first products to market. The investment and partnership with Sanofi provide that commercial validation.”

*A biologic is manufactured in a living system such as a microorganism, or plant or animal cells. Most biologics are very large, complex molecules or mixtures of molecules. Many biologics are produced using recombinant DNA technology.

As reported in Drug Delivery Business: http://bit.ly/Sanofi_Enable

News items and features like this appear in the Desang Diabetes Magazine, our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it’s free, and you can easily unsubscribe should you wish to).

Sign me up!

Open publication

Sign up to our Magazine »

Leave a Comment

Submit Comment »

No Comments Yet!